Why the study?
Does Azole reduce tumor volume and cell count in mice with Ehrlich ascites carcinoma?
Does Azole reduce tumor volume and cell count in mice with Ehrlich ascites carcinoma?
Novel azole derivatives demonstrate significant antitumor activity against Ehrlich ascites carcinoma in mice, though their use is limited by hepatorenal toxicity.
TCAR may offer an alternative to CEA in select patients; leaves open need for randomized trials versus CEA.
Transcarotid artery revascularization (TCAR) is a hybrid carotid revascularization procedure in which carotid stenting is accomplished by making an incision at the base of the neck & surgically exposing the common carotid artery. The evidence base for TCAR safety & efficacy comes from PROOF, ROADSTER, & ROADSTER 2 studies. The Society for Vascular Surgery guidelines for the treatment of carotid artery disease (2022) opine TCAR to be at least equivalent to Carotid Endarterectomy (CEA) in terms of safety & efficacy, with some potential improvements. In comparison with Transfemoral Carotid Artery Stenting (TF-CAS), the overall data demonstrates better outcomes with TCAR. In high-risk subjects like elderly more symptomatic patients with higher concurrent medical comorbidities, TCAR in fact appears to be preferable to both CEA & TF-CAS. Whereas this technique appears safe in the short-term, long-term vessel patency requires prospective follow-up studies.
No takes yet. Share an insight, caveat, or question.
FIA Danish (2023) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: